Rosetta Genomics (Rehovot, Israel; Jersey City, N.J.; Philadelphia, Penn.) has announced the commercial launch of its first diagnostic test. Known as miRview squamous, the test uses a single microRNA (miRNA) to differentiate non-small cell lung cancer (NSCLC) patients with squamous cell carcinoma from those with non-squamous carcinomas.

The test is available through Rosetta Genomics’ CLIA-certified lab in Philadelphia. It has a list price of $3170, according to a company representative. Results are available within ten days.

Rosetta Genomics was founded in 2000 to develop miRNA-based molecular diagnostics. The company plans to next launch tests to differentiate mesothelioma from adenocarcinoma, identify the origin of metastases, and predict response to ovarian cancer treatment.

For more on the miRview squamous test, see the January issue of Diagnostic Testing and Technology Report.